Physician profile

Dmitry Nesen

Pain Medicine (Physical Medicine & Rehabilitation) · New York, NY

NPI 1295886612

$2,435.43

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$495.09

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic USA, INC. $1,553.03 2019-2020
Medtronic, INC. $433.60 2021-2023 Intellis Adaptivestim, Vanta Adaptivestim
Nevro Corp. $274.33 2020-2023 Senza
Curonix LLC $100.33 2024 Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A
Pfizer INC. $25.01 2020
Scilex Pharmaceuticals INC. $19.92 2022
Ibsa Pharma INC. $17.05 2021
Mdd US Operations, LLC $12.16 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Dmitry Nesen

$2,435.43

in general payments reported 2019-2025

Years
2019-2024
Top company
Medtronic USA, INC.

https://glasscript.com/doctor/149993/dmitry-nesen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.